Loading...
Genetic Advances Will Expand Rare Disease Treatment Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
24 Aug 25
Updated
24 Aug 25
AnalystHighTarget's Fair Value
US$29.00
67.6% undervalued intrinsic discount24 Aug
US$9.41
1Y
30.5%7D
4.5%1Y
30.5%7D
4.5%